A randomized, multicentre, open-label, 6-month study to explore the efficacy and safety of enteric coated mycophenolate sodium (Myfortic) in combination with two corticosteroid regimens for the treatment of lupus nephritis

Trial Profile

A randomized, multicentre, open-label, 6-month study to explore the efficacy and safety of enteric coated mycophenolate sodium (Myfortic) in combination with two corticosteroid regimens for the treatment of lupus nephritis

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2015

At a glance

  • Drugs Mycophenolate sodium (Primary) ; Methylprednisolone; Methylprednisolone
  • Indications Lupus nephritis
  • Focus Therapeutic Use
  • Acronyms MyLupus
  • Sponsors Novartis Pharma A.G.
  • Most Recent Events

    • 14 Feb 2015 Status changed from recruiting to completed, according to European Clinical Trials Database record
    • 30 Jun 2012 Planned number of patients changed from 96 to 98 as reported by European Clinical Trials Database.
    • 01 Dec 2011 Results published in Lupus.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top